Here's What Analysts Are Forecasting For Vetoquinol SA (EPA:VETO) After Its Annual Results

Shareholders might have noticed that Vetoquinol SA (EPA:VETO) filed its annual result this time last week. The early response was not positive, with shares down 2.9% to €101 in the past week. It was an okay result overall, with revenues coming in at €529m, roughly what the analysts had been expecting. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Vetoquinol after the latest results.

Check out our latest analysis for Vetoquinol

Following the latest results, Vetoquinol's five analysts are now forecasting revenues of €551.5m in 2024. This would be a credible 4.2% improvement in revenue compared to the last 12 months. In the lead-up to this report, the analysts had been modelling revenues of €554.7m and earnings per share (EPS) of €5.00 in 2024. Overall, while the analysts have reconfirmed their revenue estimates, the consensus now no longer provides an EPS estimate. This implies that the market believes revenue is more important after these latest results.

There's been no real change to the consensus price target of €108, with Vetoquinol seemingly executing in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Vetoquinol, with the most bullish analyst valuing it at €120 and the most bearish at €95.00 per share. This is a very narrow spread of estimates, implying either that Vetoquinol is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's pretty clear that there is an expectation that Vetoquinol's revenue growth will slow down substantially, with revenues to the end of 2024 expected to display 4.2% growth on an annualised basis. This is compared to a historical growth rate of 8.8% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 4.6% annually. Factoring in the forecast slowdown in growth, it looks like Vetoquinol is forecast to grow at about the same rate as the wider industry.

The Bottom Line

The clear take away from these updates is that the analysts made no change to their revenue estimates for next year, with the business apparently performing in line with their models. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

At least one of Vetoquinol's five analysts has provided estimates out to 2025, which can be seen for free on our platform here.

We also provide an overview of the Vetoquinol Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.